CPB Ljubljana 2018 course book

Boost vs No Boost EORTC 22881-10882 Trial 1989-1996 5318 T1-2 Free margins

16.4%

50 Gy

10.2%

12%

66 Gy

6.2%

Breast failure depends on the dose

Bartelink H. Lancet Oncol. 2015 Jan; 16(1):47-56